Accessibility Menu
Q32 Bio logo

Q32 Bio(NASDAQ) QTTB

Market Cap$475.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-4%
5 Year-85%
1 Year+752%
1 Month+6%
$15.96
+0.63%
+0.10Today
After hours$15.90-$0.06 (-0.38%)
Q32 Bio last closing stock price
MetricPriceDate
Last closeUSD 15.972026-08-21
Q32 Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.41%USD 15.152026-08-14
1 month+5.9%USD 15.082026-07-22
3 month+175.34%USD 5.802026-05-22
Year to date+381.02%USD 3.322025-12-31
1 year+751.73%USD 1.882025-08-21
3 year-22.85%USD 20.702023-08-22
5 year-85.24%USD 108.182021-08-20
Since inception-4.08%USD 16.652024-03-26

Q32 Bio Financials at a Glance

Market Cap

$475.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$53.74M

Net Income (TTM)

$33.79M

EPS (TTM)

$3.00

P/E Ratio

5.32

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$15.96

Volume

341,531.625

Open

$15.89

Previous Close

$15.97

Daily Range

$15.72 - $16.29

52-Week Range

$1.62 - $23.57

Estimated Earnings Date

Nov 12, 2026

QTTB News

Medical researchers - GettyImages-1096502340

Why Q32 Bio Stock Skyrocketed Today

Joe TenebrusoJul 13, 2026
Foolcom-Featured.png

Q32 Bio (QTTB) Q2 Loss Drops 45%

Motley Fool Markets TeamAug 6, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Q32 Bio

Q32 Bio Inc. develops treatments for autoimmune diseases. These medicines help patients with hair loss and skin inflammation. The company works to fix unbalanced immune responses.

Medications in the Pipeline

  • Bempikibart: Human antibody that blocks proteins triggering immune attacks; used to treat alopecia areata, an autoimmune condition that causes hair loss.
  • ADX-914-XL: Long-acting version of bempikibart in early stages; designed to provide medical activity with fewer doses for patients.
  • Complement Platform: Specialized technology for creating drugs that stop tissue damage; includes early-stage candidates for eye and kidney diseases.

Strategic Shifts and Funding

  • Sold ADX-097 assets to Akebia Therapeutics in Nov. 2025 for $10 million in initial payments and potential future milestones.
  • Regained full development and commercial rights to bempikibart from Amgen in Nov. 2023 following a partnership termination.
  • Raised $187.6 million in net proceeds through a public stock offering in July 2026.
  • Completed a private stock placement in May 2026 that generated $53.4 million in net proceeds.

Unique Scientific Approach

The company focuses on a specific immune pathway called IL-7R alpha to treat several inflammatory diseases. This tissue-targeted approach aims to stop immune attacks in specific organs while minimizing effects on the rest of the body.

Recent Financial Performance

  • Cash and cash equivalents totaled $106.3 million as of June 30, 2026.
  • Net loss was $16.6 million for the six-month period ended June 30, 2026.
  • Research and development expenses decreased $4.8 million year over year for the first half of 2026.
  • Market capitalization was $206.4 million with a price-to-earnings ratio of -7.6 in Q2 2026.

The Bottom Line

Q32 Bio has narrowed its focus to advancing its lead drug candidate for autoimmune hair loss through registration-directed trials. Strategic asset sales and recent large-scale financing rounds have strengthened its balance sheet to support late-stage clinical development.

AI Generated • Aug 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

24

CEO

Jodie P. Morrison

Website

www.q32bio.com

Headquarters

Waltham, MA 02451, US

QTTB Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

39.94%

Net Income Margin

62.87%

Return on Equity

76.88%

Return on Capital

29.47%

Return on Assets

29.16%

Earnings Yield

18.80%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$475.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

29.77M

Volume

341.53K

Avg. Volume

1.52M

Financials (TTM)

Gross Profit

$53.74M

Operating Income

$21.46M

EBITDA

$34.62M

Operating Cash Flow

-$19.83M

Capital Expenditure

$0.00

Free Cash Flow

-$19.83M

Cash & ST Invst.

$106.27M

Total Debt

$5.30M

Q32 Bio Performance Analysis

Q32 Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,208,000-90.6%
20232023-12-31USD -6,651,000N/A
20242024-12-31USD 0N/A
20252025-12-31USD 53,737,000N/A
Q32 Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-100.0%
Q22026-06-30N/A
Q32 Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.57-95.0%
20232023-12-31USD -153.979709.3%
20242024-12-31USD -6.58-95.7%
20252025-12-31USD 2.42N/A
Q32 Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3023.1%
Q42025-12-31828.3%
Q12026-03-31-112.4%
Q22026-06-3018.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$475.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$21.61M

N/A

Employees

22

N/A

Net Income

-$8.95M

+5.7%

EBITDA

-$8.77M

+3.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$106.27M

+93.8%

Total Debt

$5.30M

-71.7%

Accounts Receivable

$2.39M

+331.0%

Inventory

$0.00

N/A

Long Term Debt

$9.12M

-22.8%

Short Term Debt

$0.00

-100.0%

Return on Assets

29.16%

N/A

Return on Invested Capital

19.43%

N/A

Free Cash Flow

-$3.08M

+71.1%

Operating Cash Flow

-$3.08M

+71.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SABSSAB Biotherapeutics, Inc.
$3.78+2.16%
ANTXAN2 Therapeutics, Inc.
$5.81+0.35%
VRCAVerrica Pharmaceuticals Inc.
$4.82-0.82%
BOLDBoundless Bio, Inc.
$3.00+3.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About QTTB

What is the current price of Q32 Bio?

Q32 Bio is trading at $15.97 per share.

What is the 52-week range for Q32 Bio?

Over the past 52 weeks, Q32 Bio has traded between $1.62 and $23.57.

How much debt does Q32 Bio have?

As of the most recent reporting period, Q32 Bio reported total debt of $5.30M.

How much cash does Q32 Bio have on hand?

Q32 Bio reported $106.27M in cash and cash equivalents in its most recent financial results.

What is Q32 Bio’s dividend yield?

Q32 Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services